Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Annika De Sousa Linhares

Showing results (1-10 of 11) with videos related to

Pageof 2
Sort By:
Iscience|March 8, 2024
Transcriptional reprogramming via signaling domains of CD2, CD28, and 4-1BBAnnika De Sousa Linhares, Sumana Sharma, Peter Steinberger, et al.
Frontiers in Immunology|September 21, 2018
Not All Immune Checkpoints Are Created EqualAnnika De Sousa Linhares, Judith Leitner, Katharina Grabmeier-Pfistershammer, et al.
Cell Communication and Signaling : CCS|May 24, 2024
The CD6 interactome orchestrates ligand-independent T cell inhibitory signalingRita F Santos, Annika de Sousa Linhares, Peter Steinberger, et al.
Methods in Molecular Biology (Clifton, N.J.)|July 4, 2026
Yeast Display of Single-Chain Fc Fragments with Modulated Binding of Effector MoleculesKatharina Stadlbauer, Cecilia Wick, Julia Gobl, et al.
European Journal of Immunology|March 31, 2020
TIM-3 and CEACAM1 do not interact in cis and in transAnnika De Sousa Linhares, Florian Kellner, Sabrina Jutz, et al.
Science Signaling|October 3, 2023
The ligand-dependent suppression of TCR signaling by the immune checkpoint receptor LAG3 depends on the cytoplasmic RRFSALE motifKatharina Aigner-Radakovics, Annika De Sousa Linhares, Benjamin Salzer, et al.
Frontiers in Immunology|October 2, 2019
Neuropilin-1 Acts as a Receptor for Complement Split ProductsClaire Battin, Annika De Sousa Linhares, Wolfgang Paster, et al.
Cancer Immunology, Immunotherapy : CII|June 13, 2023
Engineered soluble, trimerized 4-1BBL variants as potent immunomodulatory agentsClaire Battin, Annika De Sousa Linhares, Judith Leitner, et al.
Scientific Reports|August 9, 2019
Therapeutic PD-L1 antibodies are more effective than PD-1 antibodies in blocking PD-1/PD-L1 signalingAnnika De Sousa Linhares, Claire Battin, Sabrina Jutz, et al.
Proceedings of the National Academy of Sciences of the United States of America|June 20, 2020
A conformation-specific ON-switch for controlling CAR T cells with an orally available drugCharlotte U Zajc, Markus Dobersberger, Irene Schaffner, et al.
Pageof 2

Showing results (1-10 of 11) with videos related to

Sort By:
Pageof 2
Iscience|March 8, 2024
Transcriptional reprogramming via signaling domains of CD2, CD28, and 4-1BBAnnika De Sousa Linhares, Sumana Sharma, Peter Steinberger, et al.
Frontiers in Immunology|September 21, 2018
Not All Immune Checkpoints Are Created EqualAnnika De Sousa Linhares, Judith Leitner, Katharina Grabmeier-Pfistershammer, et al.
Cell Communication and Signaling : CCS|May 24, 2024
The CD6 interactome orchestrates ligand-independent T cell inhibitory signalingRita F Santos, Annika de Sousa Linhares, Peter Steinberger, et al.
Methods in Molecular Biology (Clifton, N.J.)|July 4, 2026
Yeast Display of Single-Chain Fc Fragments with Modulated Binding of Effector MoleculesKatharina Stadlbauer, Cecilia Wick, Julia Gobl, et al.
European Journal of Immunology|March 31, 2020
TIM-3 and CEACAM1 do not interact in cis and in transAnnika De Sousa Linhares, Florian Kellner, Sabrina Jutz, et al.
Science Signaling|October 3, 2023
The ligand-dependent suppression of TCR signaling by the immune checkpoint receptor LAG3 depends on the cytoplasmic RRFSALE motifKatharina Aigner-Radakovics, Annika De Sousa Linhares, Benjamin Salzer, et al.
Frontiers in Immunology|October 2, 2019
Neuropilin-1 Acts as a Receptor for Complement Split ProductsClaire Battin, Annika De Sousa Linhares, Wolfgang Paster, et al.
Cancer Immunology, Immunotherapy : CII|June 13, 2023
Engineered soluble, trimerized 4-1BBL variants as potent immunomodulatory agentsClaire Battin, Annika De Sousa Linhares, Judith Leitner, et al.
Scientific Reports|August 9, 2019
Therapeutic PD-L1 antibodies are more effective than PD-1 antibodies in blocking PD-1/PD-L1 signalingAnnika De Sousa Linhares, Claire Battin, Sabrina Jutz, et al.
Proceedings of the National Academy of Sciences of the United States of America|June 20, 2020
A conformation-specific ON-switch for controlling CAR T cells with an orally available drugCharlotte U Zajc, Markus Dobersberger, Irene Schaffner, et al.
Pageof 2